

Nancy Simonian, M.D., is founding CEO of Syros Pharmaceuticals (Nasdaq: SYRS), a biotech company pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. The company is focused on cancer and immune-mediated diseases and is advancing a growing pipeline.

Nancy has a track record of value creation in biotechnology. Under Nancy's leadership as Chief Medical Officer at Millennium, VELCADE® became a mainstay of treatment for multiple myeloma. Nancy led Millennium's clinical pipeline including NINLARO® for hematologic malignancies and ENTYVIO® for inflammatory bowel disease. At Biogen, Nancy played a central role in developing AVONEX® and TYSABRI® for multiple sclerosis.

Nancy started her career as an assistant professor at Harvard Medical School and Massachusetts General Hospital (MGH). She trained in neurology at MGH, received her M.D. from University of Pennsylvania and graduated from Princeton. She is on the board of directors of Seattle Genetics, Damon Runyon Cancer Research Foundation and the BIO's Emerging Companies Board.